Nutrition and Exercise in Critical Illness (NEXIS)

• ClinicalTrials.gov Identifier: NCT03021902
• Recruitment Status: Recruiting
• First Posted: January 16, 2017
• Last Update Posted: February 11, 2019
• Sponsor: Clinical Evaluation Research Unit at Kingston General Hospital
• Collaborators: University of Vermont; Johns Hopkins University
• Information provided by (Responsible Party): Daren K. Heyland, Clinical Evaluation Research Unit at Kingston General Hospital

Study Description

Brief Summary:

This study proposes a novel early intervention combining Intravenous (IV) amino acids plus in-bed cycle ergometry exercise to improve physical outcomes in critically ill patients. The investigators hypothesize that this innovative approach will improve short-term physical functioning outcomes (primary outcome), as well as amino acid metabolism, body composition, and patient-reported outcomes at 6-month follow-up.

Condition or disease	Intervention/treatment	Phase
Acute Respiratory Failure	Drug: IV amino acids; Device: In-bed cycle ergometry exercise	Phase 2

Detailed Description:

The evaluation of a combination of exercise and protein supplementation in intensive care unit (ICU) patients is novel and potentially very important. For instance, outside of the ICU, in other clinical conditions, the combination of protein supplementation and exercise improves protein synthesis, muscle mass, and muscle strength compared to protein or exercise alone.[63-70] Hence, an opportunity exists to improve ICU patients' physical outcomes via evaluating the combination of optimized protein intake and early exercise in the ICU setting.

The proposed intervention and hypothesis: The investigators propose a multi-centered Phase II RCT, with blinded outcomes assessment, of a combination of intravenous (IV) amino acid supplementation and early in-bed cycle ergometry exercise versus usual care in ICU patients requiring mechanical ventilation. The investigators hypothesize that this novel combined intervention will: (1) improve physical functioning at hospital discharge; (2) reduce muscle wasting with improved amino acid metabolism and protein synthesis in-hospital; and (3) improve health-related quality of life, physical functioning, and healthcare resource utilization at 6 months after enrollment. Preliminary data show feasibility and safety of IV amino acids and the proposed exercise intervention. The investigators have chosen a primary outcome that correlates well with long-term outcomes including mortality, hospitalization, and quality of life. [54] If this Phase II trial is positive, investigators will seek funding for a Phase III RCT to demonstrate sustained improvements with a longer-term patient-centered primary outcome and to examine the feasibility, and facilitators/barriers of delivery of this intervention by ICU nurses, physical therapists, and others. If proven effective, this combined intervention has potential to revolutionize care of ICU patients and have a major public health impact on the growing number of ICU survivors.

Objectives: To demonstrate that the innovative combination of amino acid supplementation plus early in-bed cycle ergometry exercise improves physical outcomes of ICU patients.

Specific Aims of Full Phase II RCT:

1. Short-term performance-based physical function outcomes. To determine if a combined IV amino acid supplementation and in-bed cycle ergometry exercise intervention, compared to usual care, improves in hospital muscle strength and performance-based physical functioning outcomes in critically ill patients, using a primary endpoint of six-minute walk distance (6MWD) at hospital discharge.
2. Body composition. To determine if the combined intervention, compared to usual care, improves amino acid utilization and decreases muscle wasting in ICU patients (secondary endpoints).
3. Patient-reported outcomes and health care utilization at 6 months. To determine if the combined intervention, compared to usual care, improves physical functioning, health-related quality of life, and healthcare utilization at 6 months after study enrollment (secondary endpoints).

NEXIS Flame mechanisitic Ancillary sub study:

In the proposed sub-study, the addition of bronchoaveloar lavages, blood sampling and muscle sampling measures during the participant's ICU stay will provide the ability to examine the effects of the NEXIS intervention on inflammation as a possible mechanism for improved muscle weakness.

Specific Aims of the NEXIS FLAME mechanistic ancillary study:

1. To determine if the NEXIS intervention attenuates the release of IL-17 and related cytokines to reduce systemic inflammation in humans.
2. To determine if the NEXIS intervention reduces lung injury and neutrophilic lung inflammation in humans.
3. To determine if the NEXIS intervention attenuates skeletal muscle fiber atrophy via down regulation of muscle proteolytic pathways.
4. To determine if the NEXIS intervention, and exercise specifically, reduces the content of inflammatory cells in skeletal muscle.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 142 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU
• Actual Study Start Date: September 28, 2017
• Estimated Primary Completion Date: March 2022
• Estimated Study Completion Date: March 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: IV amino acid + in-bed cycle ergometry; Beginning within 96 hours of initiation of mechanical ventilation, participants will receive the combined intervention that includes IV amino acids supplementation and in-bed cycle ergometry exercise	Drug: IV amino acids; IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.; Other Name: Clinisol 15% (Baxter) - sulfite-free (Amino Acid) Injection; Device: In-bed cycle ergometry exercise; In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling. Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay.; Other Name: MotoMed Letto II Cycle Ergometer
No Intervention: Usual care; Participants randomized to the usual care arm will receive usual care protein and exercise.

Outcome Measures

Primary Outcome Measures :

1. Physical functioning [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
   6-minute walk distance

Secondary Outcome Measures :

1. Overall strength-upper extremity [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
   MRC Sum-score
2. Overall strength-lower extremity [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
   MRC Sum-score
3. Quadriceps force-lower extremity strength [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
   Hand held dynamometry
4. Distal strength-hand grip strength [ Time Frame: ICU and hospital discharge (up to 26 weeks after randomization) ]
   Hand held dynamometry
5. Overall Physical Functional status - Short Physical Performance Battery [ Time Frame: ICU and hospital discharge (up to 26 weeks after randomization) ]
   Short Physical Performance Battery
6. Overall Physical Functional status - Functional Status Score - ICU [ Time Frame: ICU and hospital discharge (up to 26 weeks after randomization) ]
   Functional Status Score - ICU
7. Mortality [ Time Frame: ICU and hospital discharge (up to 26 weeks after randomization) ]
   Chart review
8. Length of ventilation [ Time Frame: ICU and hospital discharge (up to 26 weeks after randomization) ]
   Chart review
9. ICU stay [ Time Frame: ICU and hospital discharge (up to 26 weeks after randomization) ]
   Chart review
10. Hospital stay [ Time Frame: ICU and hospital discharge (up to 26 weeks after randomization) ]
    Chart review
11. ICU readmission [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
    Chart review
12. Re-intubation [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
    Chart review
13. Hospital-acquired infections [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
    Chart review
14. Discharge location (e.g. home vs. rehab) [ Time Frame: Hospital discharge (up to 26 weeks after randomization) ]
    Chart review
15. Body composition - Ultrasound [ Time Frame: Enrollment, hospital discharge, & ICU discharge (up to 26 weeks after randomization) ]
    Ultrasound of quadriceps
16. Body composition - CT - Chest when clinically available [ Time Frame: Enrollment, hospital discharge, & ICU discharge (up to 26 weeks after randomization) ]
    Chest CT
17. Body composition - CT - Abdominal Scan when clinically available [ Time Frame: Enrollment, hospital discharge, & ICU discharge (up to 26 weeks after randomization) ]
    Abdominal CT scan at 3rd lumbar vertebra
18. Health-related quality of life - SF-36 [ Time Frame: Telephone survey at 6 months ]
    36-Item Short Form Health Survey (SF-36)
19. Health-related quality of life - EQ-5D-5L [ Time Frame: Telephone survey at 6 months ]
    EuroQol Group standardized measure of health status (EQ-5D-5L)
20. Physical functioning - Katz ADL [ Time Frame: Hospital discharge (proxy) and telephone survey at 6 months ]
    Katz Index of Independence in Activities of Daily Living (Katz ADL)
21. Physical functioning - Lawton IADL [ Time Frame: Telephone survey at 6 months ]
    Lawton Instrument Activities of Daily Living Scale (Lawton IADL)
22. Physical functioning/participation - return to work [ Time Frame: Telephone survey at 6 months ]
    Return to baseline work/activity
23. Physical functioning/participation - living location [ Time Frame: Telephone survey at 6 months ]
    Living location
24. Mental and Cognitive Functioning - MoCA-BLIND [ Time Frame: Telephone survey at 6 months ]
    MoCA-BLIND
25. Mental and Cognitive Functioning - HADS [ Time Frame: Telephone survey at 6 months ]
    Hospital Anxiety and Depression Scale
26. Mental and Cognitive Functioning - IES-R [ Time Frame: Telephone survey at 6 months ]
    Impact of Events Scale
27. Health Care Resource Utilization [ Time Frame: Telephone survey at 6 months ]
    Admission to ICU, hospital, rehabilitation & nursing facility
28. Body composition - DEXA Scan [ Time Frame: Hospital Discharge ]
    Whole Body DEXA Scan
29. Body Composition - Heavy water [ Time Frame: Enrolllment, During ICU stay ]
    Fat-free and fat mass can be measured with D2O in body fluids using gas chromatography-tandem mass spectrometry.
30. Plasma and muscle protein synthesis - Heavy water [ Time Frame: Enrolllment, During ICU stay ]
    Muscle protein synthesis will be analyzed with chromatography and mass spectrometry techniques.
31. NEXIS FLAME - Circulating inflammatory mediators [ Time Frame: Enrollment, Days 3,5,and 8 ]
    Blood IL-17, IL-23, IL-6, TNFα, CXCK1, CXCL5, CXCL8, CCL2, SP-D, KL-6, vWF, and leukocyte counts with differential
32. NEXIS FLAME - Lung Inflammation [ Time Frame: Enrollment, Day 5 ]
    Bronchoalveolar lavage neutrophil counts, IL-17A, CXCL5, and protein
33. NEXIS FLAME - Muscle area [ Time Frame: Enrollment, Day 5 ]
    Single muscle fiber cross-sectional area (CSA), UPS expression, MuRF1 expression, myosin protein content (all from vastus lateralis sampling)
34. NEXIS FLAME - Muscle inflammation [ Time Frame: Enrollment, Day 5 ]
    Muscle macrophages (CD45+, CD206+)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. ≥18 years old.
2. Requiring mechanical ventilation with actual or expected total duration of mechanical ventilation ≥ 48 hours.
3. Expected ICU stay ≥ 4 days after enrollment (to permit adequate exposure to the proposed intervention).

Exclusion Criteria:

1. >96 continuous hours of mechanical ventilation before enrollment.
2. Expected death or withdrawal of life-sustaining treatments within this hospitalization.
3. No expectation for any nutritional intake within the subsequent 72 hours.
4. Severe chronic liver disease (MELD score ≥20) or acute fulminant hepatitis.
5. Documented allergy to the amino acid intervention.
6. Metabolic disorders involving impaired nitrogen utilization
7. Not ambulating independently prior to illness that lead to ICU admission (use of gait aid permitted).
8. Pre-existing primary systemic neuromuscular disease (e.g. Guillain Barre).
9. Neuromuscular blocker infusion (eligible once infusion discontinued if other inclusion criteria met).
10. Intracranial or spinal process affecting motor function
11. Pre-existing cognitive impairment or language barrier that prohibits outcomes assessment.
12. Patients in hospital >5 days prior to ICU admission
13. Lower extremity impairments that prevent cycling (e.g. amputation, knee/hip injury).
14. Remaining intubated for airway protection only
15. Weight ≥150kg
16. Physician declines patient enrollment
17. Insufficient IV access
18. Pregnant
19. Incarcerated

Contacts and Locations

Contacts

Contact: Daren K Heyland, MD, MSc; 613-548-3232 ext 4847; dkh2@queensu.ca

Contact: John Clarke, MSc; 613-549-6666 ext 4847; clarkej1@kgh.kari.net

Locations

United States, Maryland

Johns Hopkins Hospital; Recruiting

Baltimore, Maryland, United States, 21287

Contact: Dale M Needham, MD, PhD 410-955-3467 dale.needham@jhmi.edu

United States, North Carolina

Wake Forest University Baptist Medical Center; Recruiting

Winston-Salem, North Carolina, United States, 27157

Contact: Lori Flores 336-713-0008 lflores@wakehealth.edu

Contact: Daniel C Files, MD 336-716-2011 dfiles@wakehealth.edu

United States, Vermont

University of Vermont College of Medicine; Recruiting

Burlington, Vermont, United States, 05405

Contact: Sara S Ardren, PA 802-656-7953 sara.ardren@uvmhealth.org

Contact: Renee D Stapleton, MD, PhD 802-656-7975 renee.stapleton@uvm.edu

United States, Washington

Harborview Medical Center; Recruiting

Seattle, Washington, United States, 98104

Contact: Stephanie Gundel 206-744-4523 sgundel@uw.edu

Contact: Catherine L Hough, MD, MSc 206-744-4523 cterrlee@u.washington.edu

Sponsors and Collaborators

Clinical Evaluation Research Unit at Kingston General Hospital

University of Vermont

Johns Hopkins University

Investigators

• Principal Investigator: Daren K Heyland, MD, MSc; Queen's University
• Principal Investigator: Renee D Stapleton, MD, PhD; University of Vermont
• Principal Investigator: Dale M Needham, MD, PhD; Johns Hopkins University

More Information

Publications:

Burtin C, Clerckx B, Robbeets C, Ferdinande P, Langer D, Troosters T, Hermans G, Decramer M, Gosselink R. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med. 2009 Sep;37(9):2499-505. doi: 10.1097/CCM.0b013e3181a38937.

Chan KS, Pfoh ER, Denehy L, Elliott D, Holland AE, Dinglas VD, Needham DM. Construct validity and minimal important difference of 6-minute walk distance in survivors of acute respiratory failure. Chest. 2015 May;147(5):1316-1326. doi: 10.1378/chest.14-1808.

Kho ME, Truong AD, Zanni JM, Ciesla ND, Brower RG, Palmer JB, Needham DM. Neuromuscular electrical stimulation in mechanically ventilated patients: a randomized, sham-controlled pilot trial with blinded outcome assessment. J Crit Care. 2015 Feb;30(1):32-9. doi: 10.1016/j.jcrc.2014.09.014. Epub 2014 Sep 22.

Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG; Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013 Apr 18;368(16):1489-97. doi: 10.1056/NEJMoa1212722. Erratum in: N Engl J Med. 2013 May 9;368(19):1853. Dosage error in article text..

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, Morris A, Dong N, Rock P. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA. 2012 Feb 22;307(8):795-803. doi: 10.1001/jama.2012.137. Epub 2012 Feb 5.

National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014 Jun 5;370(23):2191-200. doi: 10.1056/NEJMoa1401520. Epub 2014 May 18.

Parry SM, Berney S, Koopman R, Bryant A, El-Ansary D, Puthucheary Z, Hart N, Warrillow S, Denehy L. Early rehabilitation in critical care (eRiCC): functional electrical stimulation with cycling protocol for a randomised controlled trial. BMJ Open. 2012 Sep 13;2(5). pii: e001891. doi: 10.1136/bmjopen-2012-001891. Print 2012.

Fan E, Zanni JM, Dennison CR, Lepre SJ, Needham DM. Critical illness neuromyopathy and muscle weakness in patients in the intensive care unit. AACN Adv Crit Care. 2009 Jul-Sep;20(3):243-53. doi: 10.1097/NCI.0b013e3181ac2551. Review.

Dowdy DW, Dinglas V, Mendez-Tellez PA, Bienvenu OJ, Sevransky J, Dennison CR, Shanholtz C, Needham DM. Intensive care unit hypoglycemia predicts depression during early recovery from acute lung injury. Crit Care Med. 2008 Oct;36(10):2726-33. doi: 10.1097/CCM.0b013e31818781f5.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Heyland DK, Day A, Clarke GJ, Hough CT, Files DC, Mourtzakis M, Deutz N, Needham DM, Stapleton R. Nutrition and Exercise in Critical Illness Trial (NEXIS Trial): a protocol of a multicentred, randomised controlled trial of combined cycle ergometry and amino acid supplementation commenced early during critical illness. BMJ Open. 2019 Jul 31;9(7):e027893. doi: 10.1136/bmjopen-2018-027893.

• Responsible Party: Daren K. Heyland, Director, Clinical Evaluation Research Unit at Kingston General Hospital
• ClinicalTrials.gov Identifier: NCT03021902
• Other Study ID Numbers: The NEXIS Trial
• First Posted: January 16, 2017
• Last Update Posted: February 11, 2019
• Last Verified: February 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: There is no plan to share IPD.

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Respiratory Insufficiency; Critical Illness; Respiration Disorders; Respiratory Tract Diseases; Disease Attributes; Pathologic Processes